Intervention with the hypoxic tumor cell sensitizer etanidazole in the combined modality treatment of limited stage small-cell lung cancer. A one- institution study

International Journal of Radiation Oncology Biology Physics

Volumn 40, Issue 2, 1998, Pages 337-342

  Urtasun, Raul C ^a   Palmer, Martin ^a   Kinney, Brenda ^a   Belch, Andrew ^a   Hewitt, Joanne ^a   Hanson, John ^b  

^a CROSS CANCER INSTITUTE   (Canada)

^b Div Epidemiol   (Canada)

Author keywords

Etanidazole; Hypoxic cell sensitizer; Limited stage small cell lung cancer

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETANIDAZOLE; ETOPOSIDE; VINCRISTINE;

ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG RESPONSE; ESOPHAGITIS; HUMAN; LUNG SMALL CELL CANCER; LUNG TOXICITY; NEPHROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; STATISTICAL ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; CISPLATIN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETANIDAZOLE; ETOPOSIDE; HUMANS; LUNG NEOPLASMS; PERIPHERAL NERVOUS SYSTEM DISEASES; RADIATION-SENSITIZING AGENTS; VINCRISTINE;

EID: 0032518408     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(97)00771-2     Document Type: Article

References (22)

1. 1. Arriagada, R.; Kramar, A.; Le Chevalier, T.; De Cremoux, H.; for the French Cancer Center's Lung Group. Competing events determining relapse-free survival in limited small cell lung carcinoma. J. Clin. Oncol. 10:447-451; 1992.
2. 2. Coy, P.; Hodson, D. I.; Murray, N.; Pater, J. L.; Payne, D. G.; Arnold, A.; Kostaschuk, E.; Dixon, P.; Evans, W. K.; Zee, B. Patterns of failure following loco-regional radiotherapy in the treatment of limited stage small cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys. 28:355-362; 1994.
3. 3. Gray, J. R.; Sobczak, M. L.; Hahn, S. M.; Sullivan, F. J.; Johnson, B. E.; Bridges, J. D. Analysis of local control in 150 limited stage small cell lung cancer patients treated with combined thoracic irradiation and multiagent chemotherapy (Abstr.). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 14:A1056; 1995.
4. 4. Janaki, L.; Rector, D.; Turrisi, A.; McCracken, J.; Livingston, R.; Giri, S.; Gordon, W.; Crowley, J. Patterns of failure and second malignancies from SWOG 8269: Concurrent cisplatin (P), etoposide (E), vincristine (V), and once daily radiotherapy (RT) for the treatment of limited small-cell lung cancer (Abstr.). Proc. Am. Soc. Clin. Oncol. 13:331; 1994.
5. 5. Johnson, D. H.; Turrisi, A. T.; Chang, A. Y.; Blum, R.; Bonomi, P.; Ettinger, D.; Wagner, H. Alternating chemotherapy and twice-daily thoracic radiotherapy in limited-stage small-cell lung cancer: A pilot study of the Eastern Cooperative Oncology Group. J. Clin. Oncol. 11:879-884; 1993.
6. 6. Johnson, B. E.; Bridges, J. D.; Sobczeck, M.; Gray, J.; Linnoila, R. I.; Gazdar, A. F.; Hankins, L.; Steinberg, S. M.; Edison, M.; Frame, J. N.; Pass, H.; Nesbitt, J.; Holden, D.; Mulshine, J. L.; Glatstein, E.; Ihde, D. C. Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine. J. Clin. Oncol. 14:806-813; 1996.
7. 7. Pignon, J. P.; Arriagada, R.; Ihde, D. C.; Johnson, D. H.; Perry, M. C.; Souhami, R. L.; Brodin, O.; Joss, R. A.; Kies, M. S.; Lebeau, B.; Onoshi, T.; Østerlind, K.; Tattersall, M. H. N.; Wagner, H. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N. Engl. J. Med. 327:1618-1624; 1992.
8. 8. Warde, P.; Payne, D. Does thoracic irradiation improve survival and local control in limited stage small cell carcinoma of the lung? - A meta-analysis. J. Clin. Oncol. 10:890-895; 1992.
9. 9. Murray, N.; Coy, P.; Pater, J. L.; Hodson, I.; Arnold, A.; Zee, B. C.; Payne, D.; Kostashuk, E. C.; Evans, W. K.; Dixon, P.; Sadura, A.; Feld, R.; Levitt, M.; Wierzbicki, R.; Ayoub, J.; Maroun, J. A.; Wilson, K. S. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J. Clin. Oncol. 11:336-344; 1993.
10. 10. Johnson, D. H.; Kim, K.; Turrisi, A. T.; Sause, W.; Komaki, R.; Wagner, H.; Blum, R. Cisplatin (P) and etoposide (E) + concurrent thoracic radiotherapy (TRT) administered once vs twice daily for limited-stage (LS) small cell lung cancer (SCLC): Preliminary results of an intergroup trial (Abstr.). Proc. Annu. Meet. Am. Soc. Clin. Oncol. 13:A1105; 1994.
11. 11. Stone, H. E.; Brown, J. M.; Philips, T. L.; Sutherland, R. M. Oxygen in human tumors: Correlation between methods of measurement and response to therapy. Radiat. Res. 136:422-434; 1993.
12. 2 tension measurements. Cancer Res. 51:6098-6102; 1991.
13. 123I-iodoazomycin arabinoside: preliminary report of a clinical study. Br. J. Cancer 65:90-95; 1992.
14. 3H-misonidazole to solid human tumors as a measure of tumor hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 12:1263-1267; 1986.
15. 15. Urtasun, R. C.; Parliament, M. B.; McEwan, A. J.; Mercer, J. R.; Mannan, R. H.; Wiebe, L. I.; Morin, C.; Chapman, J. D. Measurement of hypoxia in human tumours by non-invasive spect imaging of iodoazomycin arabinoside. Br. J. Cancer 74(Suppl. 27):S209-S212; 1996.
16. 16. Dish, S. Chemical sensitizer for hypoxic cells: A decade of experience in clinical radiotherapy. Radiother. Oncol. 3:97-115; 1985.
17. 17. Coleman, N. C.; Wasserman, T. H.; Urtasun, R. C.; Halsey, J.; Noll, L.; Hancock, S.; Phillips, T. L. Final report of the phase I trial of the hypoxic cell radiosensitizer SR 2508 (etanidazole), Radiation Therapy Oncology Group 83-03. Int. J. Radiat. Oncol. Biol. Phys. 18:389-393; 1990.
18. 18. Hurman, D. C.; Urtasun, R. C.; Belch, A. R.; Kinney, B.; Amy R.; Hanson, J.; Feldstein, M. Sequential wide-field radiation and systemic chemotherapy as part of the induction treatment of small cell lung cancer. Treatment modalities in lung cancer. Antibiot. Chemother. 41:161-175; 1988.
19. 19. Obergaard, J.; Hansen, S. H.; Obergaard, M; The Danish Head and Neck Cancer Study Group (DAHANCA). Randomized trials with hypoxic radiosensitizers in carcinoma of the larynx and pharynx In: Dewey, W. B. C.; Eddington, M.; Fry, M. R. G.; Hall, A. J.; Whitmore, G. F., eds. Radiation research, a 20th century perspective, Vol 2. Toronto: Academic Press: 1992:525.
20. 20. Brown, J. M.; Lemmon, M. J. SR-4233; A tumor specific radiosensitizer active in fractionated radiation regimes. Radiother. Oncol. (Suppl.)20:151-156; 1991.
21. 21. Lartigau, E.; Guichard, M. In vivo and in vitro effects of tirapazamine (SR-4233) alone or combined with radiation or cytotoxic drugs on human cell lines. Eur. J. Cancer 31A(Suppl. 15):S172; 1995.
22. 22. Minchinton, A. I.; Brown, J. M. Enhancement of the cytotoxicity of SR-4233 to normal or malignant tissues by hypoxic breeding. Br. J. Cancer 66:1053; 1992.